Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FQJW9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $38,664
Award facts
- Contract value 100% obligated
- $38,664.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $38,664.44 to DMS Pharmaceutical Group Inc. for Trikafta 100-50-75 mg/150 mg tablets (84-count units) on January 28, 2026, with completion targeted for January 29, 2026. This firm fixed-price delivery order was issued without a set-aside designation, enabling the woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois to compete in unrestricted federal procurement. DMS Pharmaceutical Group Inc. serves as a critical supplier within the Department of Defense pharmaceutical supply chain, leveraging its small business status to deliver comprehensive pharmaceutical products and medical consumables to federal agencies.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying IDC, designated as contract SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, and establishes DMS Pharmaceutical Group as a regional prime vendor contractor through December 31, 2036. The PPV-G GEN V program authorizes the issuance of firm fixed-price delivery orders for branded and generic prescription medications, over-the-counter drugs, biologics, and medical consumables to support recurring medical supply needs of military healthcare facilities worldwide, positioning DMS Pharmaceutical Group as a key supplier for Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FQJW9?
SPE2DR26FQJW9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FQJW9 worth?
The government has obligated $38,664 on SPE2DR26FQJW9.
Is contract SPE2DR26FQJW9 an order under another contract?
Yes. SPE2DR26FQJW9 is a delivery order under SPE2DR25D9135, an indefinite delivery contract.
Was contract SPE2DR26FQJW9 competed?
The extent of competition for SPE2DR26FQJW9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award